Compare CREX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CREX | LGVN |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 34.0M |
| IPO Year | 2015 | 2021 |
| Metric | CREX | LGVN |
|---|---|---|
| Price | $3.70 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 33.7K | ★ 463.2K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.86 | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,437,000.00 | $709,000.00 |
| Revenue This Year | $81.98 | N/A |
| Revenue Next Year | $14.82 | $10.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $1.97 | $0.48 |
| 52 Week High | $4.42 | $1.80 |
| Indicator | CREX | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 30.82 |
| Support Level | $3.52 | $0.74 |
| Resistance Level | $3.77 | $0.84 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 4.98 | 0.04 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The Company operates in one reportable segment, marketing technology solutions. The company provides solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.